weight loss – Dr. Barry Dworkin

Wegovy (semaglutide) now approved by Health Canada to reduce the risk of non-fatal heart attack in people with known cardiovascular disease in addition to its use for weight loss management.

November 28, 2024

Medical Mythbusting Commentary for November 28, 2024 Source:Wegovy is a weight-loss drug. Health Canada says it can now be used to curb heart-attack risk
How various treatments and strategies influence the physiology of the weight-loss plateau

April 23, 2024

Medical Mythbusting Commentary for April 24, 2024 Source:Here’s when your weight loss will plateau, according to science Reference:Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery
Sunday House Call, #909, January 14, 2024: How health insurance company wanna-be-doctor bean counter’s medication-coverage decisions interfere with therapeutic management and has had a deleterious effect on (my) patients’ health outcomes.

January 14, 2024

I talked about this before yet this continues to be a major issue in that evidence-based medicine is being thwarted by insurance companies’ decision to not provide Semaglutide (Ozempic) for the treatment and management of obesity. It is having a deleterious effect both from a mental and physical health perspective on my patients. Wasn’t the…
Could a vibrating, ingestible capsule help treat obesity? Not likely due to logistical, physiological, lifestyle factors, and whether animal models are transferable to humans.

January 3, 2024

Medical Mythbusting Commentary for January 3, 2024 Source:Could a vibrating, ingestible capsule help treat obesity? Reference:A vibrating ingestible bioelectronic stimulator modulates gastric stretch receptors for illusory satiety
TikTokers tout berberine as ‘nature’s Ozempic.’ There is little to no evidence to support this claim.

June 28, 2023

Medical Mythbusting Commentary for June 28, 2023 Source:TikTokers tout berberine as ‘nature’s Ozempic.’ Here’s why doctors say it’s not
Meta-analyses of randomized controlled trials looks at efficacy of semaglutide (Ozempic) in treating people suffering with obesity

December 19, 2022

Medical Mythbusting Commentary for December 19, 2022 Source:Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs)
Wegovy (semaglutide) approved by FDA to support people struggling to lose weight (and that includes many). Health Canada did so in November 2021. Major addition to weight-loss management options.

June 8, 2022

Medical Mythbusting Commentary for June 8, 2022 Source:Weight-loss drug called Wegovy receives FDA approval
Treatments for weight loss do exist, work well for many, and reveal our growing understanding of how our homeostatic, motivational, and executive brain centers interact with respect to weight control.

May 11, 2022

Medical Mythbusting Commentary for May 11, 2022 Source:People Taking New Hunger-Blocking Drug Lose 24 Kilograms On Average
NEJM publishes study evaluating the use of semaglutide to assist people with weight loss. Not “game-changing” but another positive step forward for evidenced-based treatment to help people with #Overweight or #Obesity.

February 16, 2021

Medical Mythbusting Commentary for February 16, 2021 Reference:Last week the NEJM published a study concluding “In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.” A follow up editorial provides some perspective.